But there are, obviously, proportionally way fewer bad outcomes created by drugs that pass Phases 2 and 3 than those that only pass Phase 1. The steepness of that attrition is literally the entire value prop of the law to begin with.
Isn't this pre-market, though?
Relative to the federal approval it's pre-market. In Montana, if your treatment is approved by a review board it's in market